Co-Diagnostics, Inc. and CoSara Diagnostics to inaugurate new oligo facility

Dec. 17, 2024
New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders.

Co-Diagnostics, Inc. announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

In support of the "Make in India" initiative, the new facility is designed to manufacture the Company's patented Co-Primers chemistry, which underpins Co-Dx's and CoSara's lab-based PCR diagnostic tests and which powers the test cups for the new Co-Dx PCR at-home and point-of-care testing platform. Qualifying under this initiative is anticipated to facilitate access to India's large and robust healthcare marketplace.

Co-Diagnostics release on PRNewswire

JLco - Julia Amaral / iStock / Getty Images Plus / Getty Images
untitled_design_11
ID 167606759 © Pop Nukoonrat | Dreamstime.com
dreamstime_xxl_167606759
ID 252304527 © Yanadee | Dreamstime.com
dreamstime_xxl_252304527
ID 12711745 © Nobilior | Dreamstime.com
dreamstime_xxl_12711745